Free Trial
NASDAQ:QLGN

Qualigen Therapeutics 7/2/2024 Earnings Report

Qualigen Therapeutics logo
$3.50 -0.12 (-3.19%)
As of 06/24/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Qualigen Therapeutics EPS Results

Actual EPS
-$17.50
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Qualigen Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Qualigen Therapeutics Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Qualigen Therapeutics' next earnings date is estimated for Tuesday, July 1, 2025, based on past reporting schedules.

Conference Call Resources

Qualigen Therapeutics Earnings Headlines

We’ve Entered the Most Bullish Phase of the Cycle
It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how to trade it, this phase brings the most potential. We’re now in that window. A free workshop outlines how a proven system is targeting daily wins, passive income, and explosive upside through curated altcoin picks. Whether you're new to crypto or looking to catch the next move with confidence, this is your roadmap. And just for showing up, you’ll receive $10 in real Bitcoin. Don’t miss it.
See More Qualigen Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Qualigen Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Qualigen Therapeutics and other key companies, straight to your email.

About Qualigen Therapeutics

Qualigen Therapeutics (NASDAQ:QLGN), a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.

View Qualigen Therapeutics Profile

More Earnings Resources from MarketBeat